EVINACUMAB (EVKEEZA®)

















  • At baseline, 94% of patients were on statins, 75% on ezetimibe, 77% on a PCSK9 inhibitor antibody, 22% on lomitapide, and 34% were receiving lipoprotein apheresis
  • Reference [1]
Effects of Evinacumab at 24 Weeks on Lipid Parameters in Patients with HoFH on Maximally Tolerated Lipid-lowering Therapy
Parameter
(average baseline value)
Evinacumab 15 mg/kg every 4 weeks
(N=43)
Placebo
(N=22)
Total
(322 mg/dl)
-47% +1%
LDL
(255 mg/dl)
-47% +2%
HDL
(44 mg/dl)
-30% +1%
Triglycerides
(124 mg/dl)
-55% -5%
Apo B -41% -5%




  • Infusion reactions include infusion site pruritus, pyrexia, muscular weakness, nausea, and nasal congestion
  • Reference [1]
Evinacumab side effects from trials lasting 24 weeks
Side effect Evinacumab
(N=81)
Placebo
(N=54)
Nasopharyngitis 16% 13%
Infusion reactions 7% 4%
Influenza-like illness 7% 6%
Dizziness 6% 0%
Rhinorrhea 5% 0%
Nausea 5% 2%
Pain in extremity 4% 0%
Asthenia 4% 0%